JP2015120698A5 - - Google Patents

Download PDF

Info

Publication number
JP2015120698A5
JP2015120698A5 JP2014262319A JP2014262319A JP2015120698A5 JP 2015120698 A5 JP2015120698 A5 JP 2015120698A5 JP 2014262319 A JP2014262319 A JP 2014262319A JP 2014262319 A JP2014262319 A JP 2014262319A JP 2015120698 A5 JP2015120698 A5 JP 2015120698A5
Authority
JP
Japan
Prior art keywords
phenyl
propanoic acid
ethynyl
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014262319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015120698A (ja
JP6101675B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015120698A publication Critical patent/JP2015120698A/ja
Publication of JP2015120698A5 publication Critical patent/JP2015120698A5/ja
Application granted granted Critical
Publication of JP6101675B2 publication Critical patent/JP6101675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014262319A 2008-07-28 2014-12-25 代謝病の治療用の化合物 Expired - Fee Related JP6101675B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409808P 2008-07-28 2008-07-28
US61/084,098 2008-07-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011520437A Division JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物

Publications (3)

Publication Number Publication Date
JP2015120698A JP2015120698A (ja) 2015-07-02
JP2015120698A5 true JP2015120698A5 (cg-RX-API-DMAC10.html) 2017-01-05
JP6101675B2 JP6101675B2 (ja) 2017-03-22

Family

ID=41076693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011520437A Pending JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物
JP2014262319A Expired - Fee Related JP6101675B2 (ja) 2008-07-28 2014-12-25 代謝病の治療用の化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011520437A Pending JP2012503595A (ja) 2008-07-28 2009-07-23 代謝病の治療用の化合物

Country Status (5)

Country Link
US (1) US8586607B2 (cg-RX-API-DMAC10.html)
EP (1) EP2313360B1 (cg-RX-API-DMAC10.html)
JP (2) JP2012503595A (cg-RX-API-DMAC10.html)
CN (2) CN102137836B (cg-RX-API-DMAC10.html)
WO (1) WO2010012650A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012136221A1 (en) * 2011-04-08 2012-10-11 Syddansk Universitet Ortho-fluoro substituted compounds for the treatment of metabolic diseases
SG194582A1 (en) * 2011-05-04 2013-12-30 Univ Sydney Prenylated hydroxystilbenes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
CA2974060C (en) * 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019074241A1 (ko) * 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
MA53188A1 (fr) * 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2023011574A1 (zh) 2021-08-05 2023-02-09 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
TR199903057T2 (xx) * 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
IL133640A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
AU1903799A (en) * 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
US6284796B1 (en) * 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US7335673B2 (en) * 2000-08-11 2008-02-26 Kaken Pharmaceutical Co., Ltd. 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP2007516258A (ja) * 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
CN1914173A (zh) * 2003-12-12 2007-02-14 惠氏公司 用于治疗心血管疾病的喹啉化合物
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JPWO2006038738A1 (ja) 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
US7582803B2 (en) * 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
RU2008136898A (ru) 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
AU2007225208A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
AU2007314405A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008071453A1 (en) * 2006-12-13 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 1,2-diarylacetylene derivatives of acyltryptophanols
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物

Similar Documents

Publication Publication Date Title
JP2015508749A5 (cg-RX-API-DMAC10.html)
JP2016028068A5 (cg-RX-API-DMAC10.html)
JP2006511474A5 (cg-RX-API-DMAC10.html)
FI3555076T3 (fi) Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja
JP2016500063A5 (cg-RX-API-DMAC10.html)
JP2007504284A5 (cg-RX-API-DMAC10.html)
JP2019513804A5 (cg-RX-API-DMAC10.html)
JP6812564B2 (ja) 肝疾患治療剤
JP2012532112A5 (cg-RX-API-DMAC10.html)
JP2012255002A5 (cg-RX-API-DMAC10.html)
JP2012504141A5 (cg-RX-API-DMAC10.html)
CN102348689A (zh) 含有羟基和/或羧基的胺与作为dhodh抑制剂的胺基烟碱酸衍生物的加成盐
JP2004504301A5 (cg-RX-API-DMAC10.html)
JP2020502111A5 (cg-RX-API-DMAC10.html)
JP2010529203A5 (cg-RX-API-DMAC10.html)
JP2004506718A5 (cg-RX-API-DMAC10.html)
JP2004529161A5 (cg-RX-API-DMAC10.html)
AU2005220728A1 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2015517525A5 (cg-RX-API-DMAC10.html)
JP2013529637A5 (cg-RX-API-DMAC10.html)
RU2015113746A (ru) Замещенные сульфонамиды
JP2019531346A (ja) 甲状腺関連副作用を低下させる方法
JP2016510741A5 (cg-RX-API-DMAC10.html)
JP2007532511A5 (cg-RX-API-DMAC10.html)
JP2013510077A5 (cg-RX-API-DMAC10.html)